α7 nicotinic acetylcholine receptors and their role in cognition. 2013

Balázs Lendvai, and Ferenc Kassai, and Agota Szájli, and Zsolt Némethy
Gedeon Richter Plc., Pharmacology and Drug Safety Department, Budapest, Gyömrői u, 19-21, Hungary. B.Lendvai@richter.hu

The precise role of nicotinic acetylcholine receptors (nAChRs) in central cognitive processes still remains incompletely understood almost 150 years after its initial discovery. Central nAChRs are activated by acetylcholine, which functions in the extracellular space as a nonsynaptic messenger. Recently, a novel concept in the nAChR mode of operation has been described as a fast-type nonsynaptic transmission. In this review, we attempt to summarise the experimental findings that support the role of one of the most distributed receptor subtypes, the α7 nAChRs, and particularly focus on its procognitive effects following receptor activation. The basic characteristics of α7 nAChRs are discussed, from receptor homology to cellular-level functions. Synaptic plasticity is often implicated with α7 nAChRs on the basis of several diverse studies. Here, we provide a summary of the plastic features of the α7 receptor subtype and its role in higher level cognitive function. Finally, recent clinical evidence is reviewed, which demonstrates with increasing confidence the promise α7 nAChRs as a molecular target in future pharmacotherapy to prevent cognitive decline in various types of dementia, specifically, via the development of positive allosteric modulator compounds.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000494 Allosteric Regulation The modification of the reactivity of ENZYMES by the binding of effectors to sites (ALLOSTERIC SITES) on the enzymes other than the substrate BINDING SITES. Regulation, Allosteric,Allosteric Regulations,Regulations, Allosteric
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D018678 Cholinergic Agents Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of ACETYLCHOLINE, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes still used in the narrower sense of MUSCARINIC AGONISTS, although most modern texts discourage that usage. Acetylcholine Agent,Acetylcholine Agents,Cholinergic,Cholinergic Agent,Cholinergic Drug,Cholinomimetic,Cholinomimetics,Muscarinic,Muscarinic Agent,Muscarinic Agents,Nicotinic Agent,Nicotinic Agents,Cholinergic Drugs,Cholinergic Effect,Cholinergic Effects,Cholinergics,Muscarinic Effect,Muscarinic Effects,Muscarinics,Nicotinic Effect,Nicotinic Effects,Agent, Acetylcholine,Agent, Cholinergic,Agent, Muscarinic,Agent, Nicotinic,Agents, Acetylcholine,Agents, Cholinergic,Agents, Muscarinic,Agents, Nicotinic,Drug, Cholinergic,Drugs, Cholinergic,Effect, Cholinergic,Effect, Muscarinic,Effect, Nicotinic,Effects, Cholinergic,Effects, Muscarinic,Effects, Nicotinic
D023421 Models, Animal Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing. Experimental Animal Models,Laboratory Animal Models,Animal Model,Animal Model, Experimental,Animal Model, Laboratory,Animal Models,Animal Models, Experimental,Animal Models, Laboratory,Experimental Animal Model,Laboratory Animal Model,Model, Animal,Model, Experimental Animal,Model, Laboratory Animal,Models, Experimental Animal,Models, Laboratory Animal
D064569 alpha7 Nicotinic Acetylcholine Receptor A member of the NICOTINIC ACETYLCHOLINE RECEPTOR subfamily of the LIGAND-GATED ION CHANNEL family. It consists entirely of pentameric α7 subunits expressed in the CNS, autonomic nervous system, vascular system, lymphocytes and spleen. Nicotinic Acetylcholine Receptor alpha7,Receptor, alpha-Bungarotoxin,alpha-Bungarotoxin Receptors,alpha7nAChR,nAChR alpha7 Subunit,Receptor, alpha Bungarotoxin,Receptors, alpha-Bungarotoxin,Subunit, nAChR alpha7,alpha Bungarotoxin Receptors,alpha-Bungarotoxin Receptor,alpha7 Subunit, nAChR

Related Publications

Balázs Lendvai, and Ferenc Kassai, and Agota Szájli, and Zsolt Némethy
May 2012, Current drug targets,
Balázs Lendvai, and Ferenc Kassai, and Agota Szájli, and Zsolt Némethy
March 2012, Biochimica et biophysica acta,
Balázs Lendvai, and Ferenc Kassai, and Agota Szájli, and Zsolt Némethy
September 2020, The Journal of general physiology,
Balázs Lendvai, and Ferenc Kassai, and Agota Szájli, and Zsolt Némethy
August 2018, Oncology letters,
Balázs Lendvai, and Ferenc Kassai, and Agota Szájli, and Zsolt Némethy
February 2012, Molecular pharmacology,
Balázs Lendvai, and Ferenc Kassai, and Agota Szájli, and Zsolt Némethy
May 2023, Nature reviews. Neurology,
Balázs Lendvai, and Ferenc Kassai, and Agota Szájli, and Zsolt Némethy
April 2023, Pharmacological research,
Balázs Lendvai, and Ferenc Kassai, and Agota Szájli, and Zsolt Némethy
October 2015, Pharmacological reviews,
Balázs Lendvai, and Ferenc Kassai, and Agota Szájli, and Zsolt Némethy
July 2021, Pharmacological reviews,
Balázs Lendvai, and Ferenc Kassai, and Agota Szájli, and Zsolt Némethy
May 2012, Current drug targets,
Copied contents to your clipboard!